A wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) has signed definitive agreements to invest $200 million for a 3% equity stake in Micro Life Sciences, the parent company of leading Indian medical devices firm Meril. This transaction pegs the company’s valuation at $6.6 billion, according to an official statement.
With this investment, Micro Life Sciences will now be backed by two prominent global investors — ADIA and Warburg Pincus.
Meril: A Homegrown MedTech Leader with Global Reach
Founded by the Bilakhia Group, Meril has emerged as a global innovator in the medical technology space. The company offers clinically advanced solutions across a wide range of specialties, including Cardiovascular, Structural Heart, Orthopaedics, Endo-surgery, In-vitro Diagnostics, and Surgical Robotics.
Headquartered in Vapi, Gujarat, Meril operates a vertically integrated, state-of-the-art manufacturing and R&D campus spread across 100 acres. The company employs over 13,000 professionals, runs more than 35 global subsidiaries, and supplies medical technologies to healthcare systems in 150 countries.
Commenting on the investment, Sanjeev Bhatt, Senior Vice President – Strategy at Meril, said:
“This strategic investment from ADIA will help us scale faster, attract top global talent, and deepen our focus on research, clinical development, and innovation — all in pursuit of our mission to enhance human life through cutting-edge healthcare solutions.”